Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Stock Information for Equillium Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Equillium Inc.

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
Equillium Announces Feedback from the U.S. Food and Drug Administration
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
EQ Inc. Announces Appointment of Interim CFO
EQ Inc. Reports Third Quarter Financial Results
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.